

Watch for Statin-Rx Interactions, Side Effects

BY MIRIAM E. TUCKER
Senior Writer

PHILADELPHIA — Be alert for potential interactions and side effects when prescribing statins, Dr. Douglas S. Paauw advised at the annual meeting of the American College of Physicians.

While hepatotoxicity and rhabdomyolysis are relatively rare, myalgias are quite common and often prompt patients to discontinue the drugs, said Dr. Paauw, professor of medicine at the University of Washington, Seattle.

And, although the overall risk of rhabdomyolysis is low, the chance is greater with the addition of other drugs.

In one frequently cited study, rates of toxicity were very low (2% myalgias, 0.4% myositis, and 0.4% hepatotoxicity) among 252 atherosclerotic patients receiving a statin plus gemfibrozil, leading the authors to conclude that the combination could be used safely in high-risk patients (*Am. Heart J.* 1999;138:151-5).

But those results may not reflect current clinical experience. Pravastatin, which is

About half of all severe cases of rhabdomyolysis occur when three or more of these agents are taken together. 'It's that third drug that markedly increases the risk.'

used less often today, was the statin most commonly used in the study (325.7 patient-years), followed by simvastatin (178.1), fluvastatin (54.0), lovastatin (20.3), and atorvastatin (15.5).

Simvastatin and lovastatin, both used more often today, are metabolized by a subunit of the cytochrome P450 system that is affected to a greater degree by gemfibrozil than are pravastatin or fluvastatin. Thus, in the study, the investigators were using "safer statins" in terms of drug interactions, Dr. Paauw noted.

If it is necessary to use both gemfibrozil and a statin—a very common scenario—it's important to document the reason for using the combination. Also, educate the patient about myalgias and rhabdomyolysis, including the importance of stopping the drug right away when muscle pain starts and then calling the physician afterward—especially if the symptoms occur during weekends or holidays.

Always ask patients about muscle pain, and monitor signs and symptoms at every office visit. There is no set policy about blood monitoring, but it's a good idea to measure creatinine phosphokinase (CPK) levels periodically and any time that symptoms develop, he advised.

Fibrates top a long list of other drugs that can increase statin toxicity, including azole antifungals, niacin, erythromycin/clarithromycin, protease inhibitors, verapamil/diltiazem, and cyclosporine. About half of all severe cases of rhabdomyolysis occur when three or more of these agents are taken together, such as in a patient who is already taking a fibrate plus a statin who is then pre-

scribed erythromycin for 2 weeks. "It's that third drug that markedly increases the risk," Dr. Paauw said.

Less attention has been paid to simple muscle pain and weakness. Published data suggest that this side effect occurs in only 1%-5% of patients on statins. "I really believe that that number is higher. In my practice, it's probably 20% at least," he said.

Indeed, patients will often take themselves off the drug and report that the pain goes away. The problem appears to be

both dose- and drug-related, with certain statins causing more problems than other drugs for some individuals.

In one study, muscle cell abnormalities were found on biopsy in patients who had normal CPK levels but who complained of muscle pain (*Ann. Intern. Med.* 2002;137:581-5). "If a CPK comes back normal, it doesn't tell us that the pain isn't from the statin. It simply tells us that the magnitude of the muscle problem doesn't put them at risk for rhabdomyol-

ysis right now, but they could still be severely debilitated by the pain."

Further complicating the picture, statin-induced muscle pain isn't necessarily uniform throughout the body. For example, a patient may complain of severe pain only in the left thigh. It may seem highly improbable that the statin is the problem, but quite often the pain goes away if you take the patient off the drug. "Take very seriously any pain syndrome in a patient on statins. If you can't find an alternative diagnosis, consider

Looking closer at patients with some acid-related disorders may reveal individual needs.



I need something that works.

I need a prescription that's covered.

I'm concerned about cost.

Effective Treatment | Formulary Access | Affordability Concerns

PREVACID HELPS GERD PATIENTS FIND HEARTBURN RELIEF (UP TO 8 WEEKS).¹

PREVACID HELPS HEAL ESOPHAGEAL EROSIONS (UP TO 8 WEEKS).¹

PREVACID IS COVERED ON 85%* OF MANAGED CARE PLANS.¹²

PREVACID SOLUTAB (LANSOPRAZOLE) ORALLY DISINTEGRATING TABLETS ARE THE LOWEST PRICED BRANDED RX PPI.³²

a short drug holiday and see what happens," Dr. Paauw recommended.

Once the pain resolves—typically in 1-2 weeks—you can restart the same statin at a low dose, or try switching to a different one. If the patient still experiences muscle pain after trying two different statins, it may be necessary to consider a different category of lipid-lowering drug.

Hepatotoxicity appears to be less of an issue with statins than was originally thought. In a retrospective cohort study of 23,000 adult HMO patients who received statins over a 5-year period, just 0.3% had severe transaminitis, defined as an alanine aminotransferase (ALT) level 10 times

greater than normal. Of those 62 patients, only 17 had ALT elevation due to the statin, and the problem resolved after stopping the statin in 16 of those 17. Most patients were symptomatic at the time of the elevation, which usually occurred within 4 weeks of starting or changing therapy (Am. J. Med. 2005;118:618-24).

Another study, which included 1,014 primary care patients taking statins who had at least one transaminase measurement, only 1% (10) had a significant elevation and another 5 had moderate elevations, but none of those cases appeared to be related to statin use (Arch. Intern. Med. 2003;163:688-92).

Based on the data, it's reasonable to monitor liver function within the first 12 weeks of therapy and perhaps annually thereafter for the first 3-4 years. After that, if the patient has been on a stable dose and has not had an ALT elevation, it's not necessary to keep going. "I don't continue to monitor for years and years," Dr. Paauw said.

Finally, grapefruit juice increases the bioavailability of drugs known to be metabolized by the CYP3A4 subunit of the P450 system, including simvastatin, lovastatin, and to a lesser degree, atorvastatin. Pravastatin, fluvastatin, and rosuvastatin do not rely on CYP3A4 and therefore do not interact with grapefruit juice.

While small amounts—a half of a grapefruit every 2 weeks, for example—are not likely to be clinically significant, a daily glass of juice at breakfast may cause a significant rise in statin bioavailability. Indeed, one study documented a 15-fold increase in mean peak serum lovastatin in 10 healthy volunteers who drank 200 mL of grapefruit juice, compared with subjects who drank water, three times a day for 3 days; subjects took one 80-mg dose of lovastatin on day 3 (Clin. Pharmacol. Ther. 1998;63:397-402). This highly significant effect may work to the advantage of some patients who have not achieved lipid control on statins, Dr. Paauw noted. ■



I want to choose how I take my medicine.

Important safety and other information

- Adverse events reported most frequently for PREVACID were diarrhea (3.8%), abdominal pain (2.1%), and nausea (1.3%).
- Symptomatic response to therapy does not preclude the presence of gastric malignancy. PREVACID formulations are contraindicated in patients with known hypersensitivity to any component of the formulation.
- PREVACID products should not be crushed or chewed.
- Individual results may vary.
- Cost comparisons do not imply any information regarding safety or efficacy.

See adjacent page for brief summary of prescribing information.

*Excludes PBMs, employers groups, and state Medicaid.
 †Based on Formulary Compass™ managed care database available through MediMedia Information Technologies, December 28, 2005. At least one PREVACID product is covered.
 ‡Based on WAC (Wholesale Acquisition Cost) pricing per oral tablet/capsule published by First DataBank, Inc., April 2006. WAC is a published price list; actual cost to pharmacy or consumer may differ.
 Phenylketonurics: PREVACID SoluTab contains phenylalanine 2.5 mg per 15 mg tablet and 5.1 mg per 30 mg tablet.

References
 1. PREVACID Complete Prescribing Information. 2. Data on file, TAP Pharmaceutical Products Inc.
 3. PREVACID I.V. Complete Prescribing Information. 4. PREVPAC Complete Prescribing Information.
 5. PREVACID NapraPAC Complete Prescribing Information.

Formulary Compass is not a trademark of TAP Pharmaceutical Products Inc.
 ©2006 TAP Pharmaceutical Products Inc. 2006-030-07908 05/06

Formulations & Indications

PREVACID HAS FORMULATIONS THAT MAY ADDRESS A BROAD RANGE OF PATIENT NEEDS.^{1,3-5}



Individual patients. Individual answers.